mesylate synthesis. Org. Process Res. Dev. 20: 100–104.71 71 Kawano, S., Ito, K., Yahata, K. et al. (2019). A landmark in drug discovery based on complex natural product synthesis. Sci. Rep. 9: 8656.
72 72 Levesque, F. and Seeberger, P.H. (2012). Continuous‐flow synthesis of the anti‐malaria drug artemisinin. Angew. Chem. Int. Ed. 51: 1706–1709.
73 73 (a) Chang, Z.Y. (2016). The discovery of Qinghaosu (artemisinin) as an effective anti‐malaria drug: a unique China story. Sci. China Life Sci. 59: 81–88.(b) Tu, Y.Y. (2011). The discovery of artemisinin (qinghaosu) and gifts from Chinese medicine. Nat. Med. 17: 1217–1220.(c) Wang, M.Y. (2016). Publication process involving the discovery of artemisinin (qinghaosu) before 1985. Asian Pac. J. Trop. Biomed. 6: 461–467.(d) Jianfang, Z. and Arnold, K.M. (2013). A Detailed Chronological Record of Project 523 and the Discovery and Development of Qinghaosu (Artemisinin). Strategic Book Publishing and Rights Company.
74 74 Gilmore, K., Kopetzki, D., Lee, J.W. et al. (2014). Continuous synthesis of artemisinin‐derived medicines. Chem. Commun. 50: 12652–12655.
75 75 Turconi, J., Griolet, F., Guevel, R. et al. (2014). Semisynthetic artemisinin, the chemical path to industrial production. Org. Process Res. Dev. 18: 417–422.
76 76 Hanada, M., Sugawara, K., Kaneta, K. et al. (1992). Epoxomicin, a new antitumor agent of microbial origin. J. Antibiot. 45: 1746–1752.
77 77 Sin, N., Kim, K.B., Elofsson, M. et al. (1999). Total synthesis of the potent proteasome inhibitor epoxomicin: a useful tool for understanding proteasome biology. Bioorg. Med. Chem. Lett. 9: 2283–2288.
78 78 Meng, L., Mohan, R., Kwok, B.H.B. et al. (1999). Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity. Proc. Natl. Acad. Sci. U. S. A. 96: 10403–10408.
79 79 Myung, J., Kim, K.B., and Crews, C.M. (2001). The ubiquitin‐proteasome pathway and proteasome inhibitors. Med. Res. Rev. 21: 245–273.
80 80 Groll, M., Kim, K.B., Kairies, N. et al. (2000). Crystal structure of epoxomicin: 20S proteasome reveals a molecular basis for selectivity of alpha',beta'‐epoxyketone proteasome inhibitors. J. Am. Chem. Soc. 122: 1237–1238.
81 81 Elofsson, M., Splittgerber, U., Myung, J. et al. (1999). Towards subunit‐specific proteasome inhibitors: synthesis and evaluation of peptide α',β'‐epoxyketones. Chem. Biol. 6: 811–822.
82 82 Rosenfeld, L. (2002). Insulin: discovery and controversy. Clin. Chem. 48: 2270–2288.
83 83 Beals, J.M. (2005). Successful Drug Discovery, vol. 1, 35–60. Weinheim: Wiley‐VCH.
84 84 Banting, F.G., Best, C.H., Collip, J.B. et al. (1922). Pancreatic extracts in the treatment of diabetes mellitus. Can. Med. Assoc. J. 12: 141–146.
85 85 Zuelzer, G. (1908). Ueber Versuche einer specifischen Fermenttherapie des Diabetes. Zeitschrift f. exp. Pathologie u. Therapie 5: 307–318.
86 86 Scott, E.L. (1912). On the influence of intravenous injections of an extract of the pancreas on experimental pancreatic diabetes. Am. J. Physiol. 29: 306–310.
87 87 Ionescu‐Tirgoviste, C. and Buda, O. (2017). Nicolae Constantin Paulescu. The First Explicit Description of the Internal Secretion of the Pancreas. Acta Med. Hist. Adriat. 15: 303–322.
88 88 Kohler, G. and Milstein, C. (1975). Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256: 495–497.
89 89 Stashenko, P., Nadler, L.M., Hardy, R., and Schlossman, S.F. (1980). Characterization of a human B lymphocyte‐specific antigen. J. Immunol. 125: 1678–1685.
90 90 Tedder, T.F., Streuli, M., Schlossman, S.F., and Saito, H. (1988). Isolation and structure of a cDNA encoding the B1 (CD20) cell‐surface antigen of human B lymphocytes. Proc. Natl. Acad. Sci. U. S. A. 85: 208–212.
91 91 Nadler, L.M., Stashenko, P., Hardy, R. et al. (1980). Serotherapy of a patient with a monoclonal‐antibody directed against a human lymphoma‐associated antigen. Cancer Res. 40: 3147–3154.
92 92 (a) Boulianne, G.L., Hozumi, N., and Shulman, M.J. (1984). Production of functional chimaeric mouse/human antibody. Nature 312: 643–646.(b) Morrison, S.L., Johnson, M.J., Herzenberg, L.A., and Oi, V.T. (1984). Chimeric human antibody molecules: mouse antigen‐binding domains with human constant region domains. Proc. Natl. Acad. Sci. U. S. A. 81: 6851–6855.
93 93 (a) Lampson, L.A. and Levy, R. (1979). A role for clonal antigens in cancer diagnosis and therapy. J. Natl. Cancer Inst. 62: 217–220.(b) Levy, R., Warnke, R., Dorfman, R.F., and Haimovich, J. (1977). The monoclonality of human B‐cell lymphomas. J. Exp. Med. 145: 1014–1028.
94 94 Miller, R.A., Maloney, D.G., Warnke, R., and Levy, R. (1982). Treatment of B‐cell lymphoma with monoclonal anti‐idiotype antibody. N. Engl. J. Med. 306: 517–522.
95 95 Pierpont, T.M., Limper, C.B., and Richards, K.L. (2018). Past, present, and future of rituximab – the world's first oncology monoclonal antibody therapy. Front. Oncol. 8: 163.
96 96 Maloney, D.G., Liles, T.M., Czerwinski, D.K. et al. (1994). Phase‐I clinical‐trial using escalating single‐dose infusion of chimeric anti‐Cd20 monoclonal‐antibody (Idec‐C2b8) in patients with recurrent B‐cell lymphoma. Blood 84: 2457–2466.
97 97 Brady, R.O., Kanfer, J.N., Bradley, R.M., and Shapiro, D. (1966). Demonstration of a deficiency of glucocerebroside‐cleaving enzyme in Gaucher's disease. J. Clin. Invest. 45: 1112–1115.
98 98 Brady, R.O., Pentchev, P.G., Gal, A.E. et al. (1974). Replacement therapy for inherited enzyme deficiency – use of purified glucocerebrosidase in Gauchers‐disease. New Engl. J. Med. 291: 989–993.
99 99 Brady, R.O. and Barton, N.W. (1994). Enzyme replacement therapy for Gaucher disease – critical investigations beyond demonstration of clinical efficacy. Biochem. Med. Metab. B 52: 1–9.
100 100 Brady, R.O. and Barton, N.W. (1996). Enzyme replacement and gene therapy for Gaucher's disease. Lipids 31: S137–S139.
101 101 Deegan, P.B. and Cox, T.M. (2012). Imiglucerase in the treatment of Gaucher disease: a history and perspective. Drug Des. Dev. Ther. 6: 81.
102 102 Breslow, R. (2016). Successful Drug Discovery, vol. 2 (ed. W.E.C. János Fischer), 1–11. Weinheim: Wiley‐VCH.
103 103 Yoshida, M., Kijima, M., Akita, M., and Beppu, T. (1990). Potent and specific‐inhibition of mammalian histone deacetylase both invivo and invitro by trichostatin‐A. J. Biolumin. Chemilumin. 265: 17174–17179.
104 104 Finnin, M.S., Donigian, J.R., Cohen, A. et al. (1999). Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature 401: 188–193.
105 105 Kelly, W.K., Richon, V.M., O'Connor, O. et al. (2003). Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. Clin. Cancer Res. 9: 3578–3588.
106 106 Molina, A.M., Van Der Mijn, J.C., Christos, P. et al. (2020). NCI 6896: a phase I trial of vorinostat (SAHA) and isotretinoin (13‐cis retinoic acid) in the treatment of patients with advanced renal cell carcinoma. Invest. New Drugs.
107 107 Schiedel, M. and Conway, S.J. (2018). Small molecules as tools to study the chemical epigenetics of lysine acetylation. Curr. Opin. Chem. Biol. 45: 166–178.
108 108
